tbuckley/cabot-search huggingface dataset:
Chemical biology and cancer drug discovery: A Johns Hopkins perspective.
Authors: Philip Cole
Journal: Cancer Research (2004)

The traditional view of the role of chemistry in research on cancer has been that it serves a synthetic function to make therapeutic agents. While drug development is still an important component of the chemistry-cancer interface, there recently has been an expansion of opportunities that extend to the drug discovery and pathophysiologic realms. I will describe the development and application of chemical and biochemical technologies being investigated in a number of labs at Johns Hopkins that can be used to dissect cancer-related signaling and transcriptional pathways. These research programs naturally lend themselves to rich collaborative opportunities between cancer biologists and chemists. Moreover, the modern cancer-chemistry interface stimulates the training of a new wave of oncologists as they strive to achieve the important goals of better diagnosis and treatment of neoplastic diseases.
Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma
Authors: M.W. Rohaan, R. Gomez-Eerland, M H Geukes Foppen, M. van Zon, R. de Boer, N.A.M. Bakker, L.M. Pronk, A. Sari, H.A. Mallo, B.A. van de Wiel, F. Lalezari, J.H. Beijnen, B. Nuijen, H. van Tinteren, J.V. van Thienen, C.U. Blank, S. Wilgenhof, T.N. Schumacher, J.H. van den Berg, J B A G Haanen
Journal: Annals of Oncology (2019)
Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Authors: M.R. Migden, A. Paccaly, K.P. Papadopoulos, F. Yang, J.D. Davis, R. Rippley, I. Lowy, M.G. Fury, E. Stankevich, D. Rischin
Journal: Annals of Oncology (2019)
Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility—Pandora’s Box Is Opening Wider
Authors: Mark Robson, Susan Domchek
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning
Authors: H. Vanacker, E. Angevin, A. Hollebecque, R. Sun, E. Deutsch, A. Zynovyev, L. Calzone, E. Barillot, C. Massard, L. Verlingue
Journal: Annals of Oncology (2019)
KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: D.P. Petrylak, B. Li, C. Schloss, K. Fizazi
Journal: Annals of Oncology (2019)
Disabled man can appeal order that saw him forcibly removed from his home at 3 am
Authors: Clare Dyer
Journal: BMJ (2019)

A man with Duchenne muscular dystrophy who was forcibly removed from his home at 3 am and taken to hospital after a judge made an emergency order has been given permission to appeal against the order three and a half years later.1

Aamir Mazhar had full mental capacity to take decisions about his treatment when the order was made in April 2016. Birmingham Community Healthcare NHS Foundation Trust had given the emergency judge, Mr Justice Mostyn, information that “was wrong and may have been untruthful,” another High Court judge, Sir Ernest Ryder, declared later.

Mazhar sued the trust and the Lord Chancellor, the minister responsible for judges. The trust paid him £10 000 (€11 213; $12 294) in an out of court settlement. But his claim against …
Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30
Authors: E. Santana, F.P. Costa, Y. Setogute, L. Carvalho, P. Lima, M. Sousa, B. Gunz, F. Azevedo, J. Sabbaga, M. Santos, T. Biachi, D. Jardim, D. Freitas, N. Horvat, R. Otaviano, L. Testagrossa, A. Iemma, F. Soares, J. Tuszynski
Journal: Annals of Oncology (2019)
The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials
Authors: Edda Pjrek, Michaela-Elena Friedrich, Luca Cambioli, Markus Dold, Fiona Jäger, Arkadiusz Komorowski, Rupert Lanzenberger, Siegfried Kasper, Dietmar Winkler
Journal: Psychotherapy and Psychosomatics (2019)

Bright light therapy (BLT) has been used as a treatment for seasonal affective disorder (SAD) for over 30 years. This meta-analysis was aimed to assess the efficacy of BLT in the treatment of SAD in adults.We performed a systematic literature search including randomized, single- or double-blind clinical trials investigating BLT (≥1,000 lx, light box or light visor) against dim light (≤400 lx) or sham/low-density negative ion generators as placebo. Only first-period data were used from crossover trials. The primary outcome was the post-treatment depression score measured by validated scales, and the secondary outcome was the rate of response to treatment.A total of 19 studies finally met our predefined inclusion criteria. BLT was superior over placebo with a standardized mean difference of -0.37 (95% CI: -0.63 to -0.12) for depression ratings (18 studies, 610 patients) and a risk ratio of 1.42 (95% CI: 1.08-1.85) for response to active treatment (16 studies, 559 patients). We found no evidence for a publication bias, but moderate heterogeneity of the studies and a moderate-to-high risk of bias.BLT can be regarded as an effective treatment for SAD, but the available evidence stems from methodologically heterogeneous studies with small-to-medium sample sizes, necessitating larger high-quality clinical trials.
Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration
Authors: Robyn H. Guymer, Philip J. Rosenfeld, Christine A. Curcio, Frank G. Holz, Giovanni Staurenghi, K. Bailey Freund, Steffen Schmitz-Valckenberg, Janet Sparrow, Richard F. Spaide, Adnan Tufail, Usha Chakravarthy, Glenn J. Jaffe, Karl Csaky, David Sarraf, Jordi M. Monés, Ramin Tadayoni, Juan Grunwald, Ferdinando Bottoni, Sandra Liakopoulos, Daniel Pauleikhoff, Sergio Pagliarini, Emily Y. Chew, Francesco Viola, Monika Fleckenstein, Barbara A. Blodi, Tock Han Lim, Victor Chong, Jerry Lutty, Alan C. Bird, Srinivas R. Sadda
Journal: Ophthalmology (2019)
Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial
Authors: D. Cunningham, R. Salazar, A. Sobrero, M.P. Ducreux, E. Van Cutsem, W. Scheithauer, C. Tournigand, V. Molnar, M. Starke, M. Baumann, E. Wiegert, M. Schmidt, D. Arnold
Journal: Annals of Oncology (2019)
Wnt/β-Catenin Pathway Affects the Cell-Fate Decisions of Hematopoietic Stem/Progenitor Cells Modulating the Epigenetic States of Various Essential Transcription Factors
Authors: Hirokazu Tanaka, Itaru Matsumura, Yusuke Satoh, Sachiko Ezoe, Tatsutoshi Nakahata, Yuzuru Kanakura
Journal: Blood (2008)
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Authors: K. Moore, A. Oza, N. Colombo, A. Oaknin, G. Scambia, D. Lorusso, R. Farias-Eisner, S. Banerjee, C. Murphy, J. Tanyi, H. Hirte, J. Konner, P. Lim, M Prasad Hayes, B. Monk, S. Kim, J. Wang, P. Pautier, I. Vergote, M. Birrer
Journal: Annals of Oncology (2019)
EGFR mutation is not a prognostic factor in completely resected lymph node–negative pulmonary adenocarcinoma (LNNPA)
Authors: N. Leeladejkul, P. Chantranuwat, P. Sitthideatphaiboon, C. Teerapakpinyo, S. Shuangshoti, V. Benjacholamas, N. Pornpattanarak, C. Vinayanuwattikun, V. Sriuranpong
Journal: Annals of Oncology (2019)
Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: A prospective observational study (PRELUDE study)
Authors: M. Ikeda, Y. Maruki, M. Ueno, T. Ioka, A. Naganuma, M. Furukawa, N. Mizuno, T. Uwagawa, Y. Nakai, M. Kanai, A. Asagi, S. Shimizu, A. Miyamoto, S. Yukisawa, M. Kadokura, T. Yamanaka, Y. Arai, T. Shibata, C. Morizane, T. Okusaka
Journal: Annals of Oncology (2019)
Patient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer
Authors: F. Ye, J. You, L. Xia, J. Lian, R. Xiao, T. Ran, X. Gao, J. Li, X. Zhao, J. Gao, H. Lin, J. Zheng, W. Liu
Journal: Annals of Oncology (2019)
Radiomics improves response evaluation for desmoid tumours treated with chemotherapy
Authors: None Crombe, M. Kind, I.L. Ray-Coquard, N. Isambert, C.M. Chevreau, T. Andre, C. Lebbe, A Le Cesne, E. Bompas, S. Piperno-Neumann, E. Saada-Bouzid, J.-Y. Blay, A. Italiano
Journal: Annals of Oncology (2019)
Liver-Derived Signals Sequentially Reprogram Myeloid Enhancers to Initiate and Maintain Kupffer Cell Identity
Authors: Mashito Sakai, Ty D. Troutman, Jason S. Seidman, Zhengyu Ouyang, Nathanael J. Spann, Yohei Abe, Kaori M. Ego, Cassi M. Bruni, Zihou Deng, Johannes C.M. Schlachetzki, Alexi Nott, Hunter Bennett, Jonathan Chang, BaoChau T. Vu, Martina P. Pasillas, Verena M. Link, Lorane Texari, Sven Heinz, Bonne M. Thompson, Jeffrey G. McDonald, Frederic Geissmann, Christopher K. Glass
Journal: Immunity (2019)
Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)
Authors: G.R. Oxnard, E.A. Klein, M.V. Seiden, E. Hubbell, O. Venn, A. Jamshidi, N. Zhang, J.F. Beausang, S. Gross, K.N. Kurtzman, E.T. Fung, B. Allen, A.P. Fields, H. Liu, M.A. Sekeres, D.A. Richards, P.P. Yu, A.M. Aravanis, A.-R. Hartman, M.C. Liu
Journal: Annals of Oncology (2019)
Medical Deferred Action — Living on Borrowed Time
Authors: Lakshmi Ganapathi, Adolfo Caldas, Jacqueline Miranda, Julia R. Köhler, Gary Visner, Gregory Sawicki
Journal: New England Journal of Medicine (2019)

Interview with Dr. Lakshmi Ganapathi on threats to medical deferred action. (11:49)Download Eliminating medical deferred action for immigrant children with highly complex conditions or the immigrant parents of U.S.-citizen children with such conditions would be a death sentence. How can physicians stand up to an administration that threatens patients' lives?
Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD
Authors: K. Fizazi, P. Gonzalez Mella, D. Castellano, J.N. Minatta, A. Rezazadeh Kalebasty, D. Shaffer, J.C. Vazquez Limon, A.J. Armstrong, H.M. Sanchez Lopez, B. Sharkey, A. Saci, J. Li, X. Wang, M. Ciprotti, P. Sathyanarayana, F. Saad, D.P. Petrylak, M.M. Retz, R.K. Pachynski, C. Drake
Journal: Annals of Oncology (2019)
Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)
Authors: C. Nangia, P. Soon-Shiong, S. Rabizadeh, J.H. Lee, L. Sender, F. Jones, M. Kistler, K. Niazi, T. Seery, A. Rock, O. Jafari
Journal: Annals of Oncology (2019)
P2.03-10 Gene Mutational Profiling Of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS
Authors: C. Xu, W. Wang, Y. Zhu, W. Zhuang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017
Authors: Donatella Baronciani, Ariane Boumendil, Arnaud Dalissier, Javid Gaziev, Ardeshir Ghavamzadeh, Josu de la Fuente, Marco Zecca, Amal Al-Seraihy, O. Alphan Kupesiz, Abdelghani Tbakhi, Gerard Socie, Vassiliki Kitra-Roussou, Arjan Lankester, Gian Luca Forni, Peter Bader, Emanuele Angelucci
Journal: Blood (2018)
A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours
Authors: J. Sarantopoulos, G. Fotopoulos, F Y -C Tsai, M.S. Beg, A.A. Adjei, Y. Lou, M. Seetharam, M.A. Villalona-Calero, J. Melear, M. Janat-Amsbury, H. Beever, L. Mouritsen, M. Wade, B.V. Bryan, D.J. Bearss
Journal: Annals of Oncology (2019)
Unravelling omics landscape and targeting oncogenic pathways in undifferentiated pleomorphic sarcomas (UPS)
Authors: M. Toulmonde, C. Lucchesi, S. Verbeke, A. Crombe, V. Chaire, A. Laroche, F Le Loarer, F. Bertucci, J. Adam, F. Bertolo, D. Geneste, L. Bianchini, B. Dadone-Montaudie, T. Hembrough, F. Cecchi, F. Giles, A. Italiano
Journal: Annals of Oncology (2019)
Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease
Authors: J. Ettl, R.G.W. Quek, H. Bhattacharyya, H.S. Rugo, S.A. Hurvitz, A. Gonçalves
Journal: Annals of Oncology (2019)
177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours: A single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)
Authors: A J A T Braat, R. van Rooij, R.C.G. Bruijnen, M N G J A Braat, F. Wessels, R.S. van Leeuwaarde, M. van Treijen, H W A M de Jong, M G E H Lam
Journal: Annals of Oncology (2019)
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Authors: D. Berton-Rigaud, A. Floquet, D. Mollon-Grange, A. Dechartres, W. Lescaut, M.-C. Kaminsky-Forrett, O. Tredan, R. Largillier, A.M. Savoye, J. Alexandre, C. Delbaldo, E. Malaurie, H. Barletta, C. Bosacki, C Garnier Tixidre, P. Follana, H. Laharie-Mineur, C.-B. Levaché, E. Pujade-Lauraine, F. Selle
Journal: Annals of Oncology (2019)
Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry
Authors: S.P.P. Gampenrieder, G. Rinnerthaler, A. Petzer, C. Tinchon, D. Fuchs, M. Balic, S. Heibl, H. Rumpold, D. Egle, A.F. Zabernigg, C.F. Singer, J. Andel, M. Hubalek, M. Knauer, R. Greil
Journal: Annals of Oncology (2019)
PB2031 INVASIVE ASPERGILLOSIS IN ELDERLY ONCOHEMATOLOGICAL PATIENTS
Authors: O. Shadrivova, E. Desyatik, A. Volkova, M. Popova, O. Uspenskaya, T. Shneyder, J. Melekhina, T. Bogomolova, S. Ignatyeva, L. Zubarovskaya, B. Afanasyev, N. Klimko
Journal: HemaSphere (2019)

Background: Invasive aspergillosis (IA) in elderly patients is not well understood. Aims: Analysis of underlying diseases, risk factors, etiology, clinical features, treatment and survival rates in elderly patients with IA. Methods: Retrospective analysis of the register data in 1998‐2018 yy. We included 646 adultpatients with proven and probable IA. For diagnosis of IA we used criteria EORTS/MSG, 2008. Results: In group I we included 137 patients with IA ≥ 60 years old, males – 60%. The control group consisted of 509 patients aged from 18 to 59 years, males – 53%. Oncohematological diseases were less frequent in elderly patients – 77% vs 87%, p = 0,002. In this patients non‐Hodgkin's lymphoma prevailed (35% vs 13%, p &lt;0.05) among underlying diseases, whereas other hematologic diseases were less common: acute lymphoblastic leukemia (6% vs 13%, p &lt; 0.05), Hodgkin's lymphoma (6% vs 13%, p &lt; 0.05). Non‐hematological diseases were more frequent in elderly patients (23% vs 13%, p = 0.002). We identified differences in risk factors between the two groups: prolonged agranulocytosis was detected in 59% vs 75%, (p = 0.0003), lymphocytopenia ‐ 45% vs 60%, (p = 0.002).Significantly smaller numbers of elderly patientswere recipients of allogeneic stem cell transplants (3% vs 26%, p = 0.00001) and received immunosuppressive therapy (17% vs 31%, p = 0.0002). No significant differences were obtained in the localization of the fungal infection, as well as in clinical symptoms and results of galactomannan test. Aspergillus spp. were isolated more often in elderly patients (52% vs 40%, p = 0,01). The main etiological agents were A. fumigatus (59% vs 45%) and A. niger (25% vs 34%). Mixed fungal infection was found in 9% vs 11% patients. Antifungal therapy was used in most of patients, the main drug used was voriconazole (73% vs 72%). Twelve weeks overall survival rate was 82% vs 79%. Summary/Conclusion: Oncohematological diseases were less frequent in elderly patients – 77%.The features of risk factors in elderly patients was less severe immunosuppression: prolonged agranulocytosis – 59%, lymphocytopenia – 45%, immunosuppressive therapy ‐ 17%, allogeneic stem cell transplants – 3%. The overall 12‐week survival in elderly patients with IA was not significantly different (82% vs 79%).
Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.
Authors: Sule Mine Bakanay, Klara Dalva, Berna Elif Koksoy, Erol Ayyildiz, Muhit Ozcan, Osman Ilhan, Meral Beksac
Journal: Blood (2012)
Induction of tumour-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Authors: T. Kojima, T. Marafioti, T. Fujiwara, Y. Shirakawa, T. Nakatsura, K. Kato, I. Puccio, T. Hikichi, S. Yoshimura, T. Nakagawa, M. Furukawa, K. Stoeber, M. Nagira, N. Ide, H. Daiko
Journal: Annals of Oncology (2019)
The expression of HER2-gene polymorphisms -1985G&gt;T and P1170A C&gt;G and their association with the risk of development of lung adenocarcinoma
Authors: I. Aleric, D. Katalinic, A. Vcev, E. Kattner, S. Bildat, V. Krieger-Borgstaedt, L. Toetome
Journal: Annals of Oncology (2019)
Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia
Authors: Daniel W. Lee, Maryalice Stetler-Stevenson, Marianna Sabatino, Constance Yuan, Terry J Fry, Nirali N Shah, Cindy Delbrook, Bonnie Yates, Hua Zhang, Ling Zhang, Nick Tschernia, Yongzhi Cui, Steven Feldman, James N Kochenderfer, Steven A. Rosenberg, David F. Stroncek, Alan S. Wayne, Crystal L Mackall
Journal: Blood (2014)
Pre-specified interim analysis of the SAFE trial (NCT2236806): A 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab
Authors: L. Livi, G. Barletta, F. Martella, I. Desideri, V. Scotti, C. Becherini, C. Saieva, F. Terziani, C. Bacci, M. Airoldi, G. Allegrini, D. Amoroso, F. Venditti, R. Tarquini, L. Orzalesi, L. Sanchez, M. Bernini, J. Nori, L. Fioretto, I. Meattini
Journal: Annals of Oncology (2019)
Abstract 18992: Kappa Opioid Receptor Improves Postresuscitation Myocardial Dysfunction via Activation of Grk3 and Phosphorylation of Erk
Authors: Yi Shan, Jian Wan, Zhaofen Lin, Jinhao Zheng, Zhigang Huang
Journal: Circulation (2015)

Objective: To investigate the signaling pathway of kappa opioid receptor (κ-OR) on postresuscitation myocardial protection. Method: A total of 120 male SD rats were randomized into control group (n=40), κ-OR agonist group (n=40) and κ-OR inhibitor group (n=40). Asphyxia-induced cardiac arrest was performed by turning-off the ventilator and clamping the endotracheal tube. Cardiac arrest was started when systolic blood pressure dropped below 25mmHg. CPR with chest compression and mechanical ventilation were started 6mins after cardiac arrest. Normal saline (1ml/kg), U50488H (ΚOR agonist, 1mg/kg) or GNTI(ΚOR inhibitor, 0.5mg/kg) was injected from on set of CPR in each group. The baseline blood gas, HR, SBP, DBP, MAP, dP/dtmax and -dP/dtmax were measured. The rat hearts were harvested at 1h, 2h, 6h, 12h and 24h post resuscitation (PR). The expression of both total κ-OR and phosphorylated κ-OR in myocaridum were determined, the likely signaling pathway molecules of G protein receptor kinase 3(GRK3) and ERK1/2 were detected. Results: The postresuscitation myocardial function, include HR, SAP, MAP, dP/dtmax and -dP/dtmax were improved in κ-OR agonist group compared to κ-OR inhibitor and control group, specifically after PR2h(p&lt;0.01).Both phosphorylated κ-OR and GRK3 protein impression were significantly increased in κ-OR agonist group, in comparison to κ-OR inhibitor group and control group (p&lt;0.01). Positive linear correlation was observed between κ-OR and GRK3. The ERK1/2 mRNA and protein expression were significantly increased in κ-OR agonist group and significantly decreased in κ-OR inhibitor group, in comparison to control group(p&lt;0.05). Conclusion: The activation of κ-OR improves postresuscitation myocardial dysfunction. The protective effects of κ-OR may via activation of GRK3 and ERK1/2 signaling pathway.
Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients
Authors: G. Mouillet, J. Fritzsch, A. Thiery-Vuillemin, N. Meneveau, H. Almotlak, L. Mansi, E. Curtit, S. Kim, M. Jary, T. Maurina, G. Eberst, P. Barthelemy, J.-C. Eymard, L. Geoffrois, O. Djoumakh, A. Anota, O. Adotevi, V. Westeel, S. Paget-Bailly
Journal: Annals of Oncology (2019)
Capecitabine and oxaliplatin as first-line chemotherapy in patients with metastatic colorectal carcinoma
Authors: C. Gennatas, V. Michalaki, S. Gennatas, A. Kondi-Paphiti, D. Voros, V. Smyrniotis
Journal: Journal of Clinical Oncology (2006)

13578 Background: Capecitabine is an oral fluoropyrimidine with superior activity and safety compared with bolus 5-FU/LV in metastatic colorectal cancer (CRC). The aim of this study was to evaluate the efficacy and safety of a combination of capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced CRC. Methods: Fourty-six patients (26 men and 20 women) with metastatic CRC entered this study. All patients were treated with capecitabine (1,000mg/m 2 p.o.twice daily, days 1–14) and oxaliplatin (130mg/m 2 on day 1). Cycles were repeated every 21 days until disease progression or unacceptable toxicity. Baseline characteristics: Median age 61 years (range 32–74), main sites of metastasis: Liver 32 patients (70%), liver and lungs 4 patients (9%), lungs 3 patients (6%), other sites 7 patients (15%). Results: 2 patients (4%) achieved complete response (CR), 17 patients (37%) achieved partial response (PR) and 7 patients (15%) attained stable disease (SD). With a median follow-up of 22 months the progression free survival was 7.5 months and overall survival was 19.0 months. All patients were assessable for toxicities. The most commonly encountered adverse events were from the gastrointestinal system (all grades 48%, grade 3, 6%). Neither toxic death nor life-threatening febrile neutropenia were reported. Conclusions: The combination of capecitabine and oxaliplatin is a convenient regimen in patients with advanced CRC that is associated with considerable efficacy and limited toxicity. No significant financial relationships to disclose.